Bronchogen
- Category
- Bioregulators
- Administration routes
- InjectableOral
- Regulatory status
- Not FDA-approved
Bronchogen is a short synthetic peptide marketed to repair bronchial cells and support airway gene regulation and mucus balance. Evidence is thin: benefits are low-confidence, based mainly on animal and mechanism-level work by one Russian group with no independent replication or human trials. The key gap is safety, with no established human safety profile or bioavailability data. It is not FDA-approved and sold only as an unregulated research compound.
This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer
Compiled from published research indexed through March 2026.
Overview
Bronchogen is a synthetic four-amino-acid peptide (Ala-Glu-Asp-Leu) developed through the Khavinson bioregulatory peptide program in Russia. It is designed to specifically target respiratory and lung tissue, where it modulates gene expression to support bronchial cell health and differentiation. It belongs to the Cytogens family of short peptide bioregulators.
How it works in the body
A short bioregulator peptide (Ala-Glu-Asp-Leu) that targets bronchial epithelial cells. It interacts with specific DNA sequences in these cells to normalize gene expression related to mucus production, ciliary function, and respiratory epithelial repair.
Research overview
Bronchogen works through an unusual mechanism for a peptide: rather than binding to cell surface receptors, it enters cells and interacts directly with DNA, activating genes critical for lung development and airway protection. In lab studies, it stimulates the maturation of bronchial lining cells, boosts local immune defenses (secretory IgA), and enhances surfactant production — the substance that keeps lung airways open. In animal models of chronic obstructive pulmonary disease (COPD), it reversed several hallmarks of the disease including excess mucus-producing cells, tissue damage, and inflammation while restoring healthy ciliated cells. It shows preferential activity in aged cell cultures, suggesting it may be most effective in older or damaged tissue. However, virtually all published research comes from a single research group (the Khavinson group in St. Petersburg), and no independent replication or controlled human clinical trials have been conducted in Western institutions.
Who researches Bronchogen?
Commonly researched by
People exploring tissue repair and injury recovery
Studied for effects on wound healing, tendon/ligament repair, or recovery from injury.
People researching inflammation management
Studied for anti-inflammatory effects across various conditions.
People researching respiratory health
Studied for effects on lung function, bronchial health, or respiratory tissue.
Important considerations for
Those who are pregnant or breastfeeding
AbsoluteNo human reproductive safety data exists for this peptide. Effects on fetal development are unknown.
Anyone under 18
AbsoluteNo pediatric safety data. Not recommended for use in minors.
Those with Known hypersensitivity
AbsoluteDiscontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).
Safety & interactions
General cautions
Pregnancy or breastfeeding
AbsoluteNo human reproductive safety data exists for this peptide. Effects on fetal development are unknown.
Children under 18
AbsoluteNo pediatric safety data. Not recommended for use in minors.
Known hypersensitivity
AbsoluteDiscontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).
How to read the ratings
- Benefits
- = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
- Risks
- = level of concern: High · Moderate · Low · Theoretical
- Interactions
- = direction with this peptide: Protective / Synergistic · Caution · Neutral
Risk summary(9)
Rated by level of concern
No human clinical trials — safety and efficacy in humans unestablished
HighClinicalTrials.gov and PubMed searches returned no human trials
Almost all research from single Russian research group (Khavinson) — no independent Western replication
ModeratePMID 25015171; PMID 26468022
Theoretical concern: gene expression modulation (NKX2-1, FOXA1/2) could affect pre-existing lung malignancies
TheoreticalPMID 22383183 (shows opposite/context-dependent roles, not unidirectional oncogenic); PMID 25015171
Potential immune enhancement via sIgA upregulation may be contraindicated in autoimmune lung conditions
TheoreticalPMID 26468022
Long-term effects of chronic DNA-binding peptide administration unknown
TheoreticalPMID 25015171; PMID 26468022
Oral bioavailability not rigorously characterized in peer-reviewed studies
ModerateNo PK study identified; parenteral dosing per secondary sources (route not confirmed in PMID 26468022 abstract)
Quality varies significantly among unregulated products sold online — no pharmaceutical-grade manufacturing standards
ModerateNo FDA approval or USP monograph exists for this tetrapeptide
Pregnancy and lactation safety data absent
ModerateNo reproductive toxicology study identified
Interactions with bronchodilators, corticosteroids, and immunosuppressants unstudied
ModerateNo published co-administration or interaction study
Interaction summary(7)
Rated by direction with this peptide
Mucolytics / mucus-reducing therapy (N-acetylcysteine, carbocisteine, erdosteine)
CautionTheoreticalThe peptide is reported to upregulate mucin genes (MUC4, MUC5AC) in bronchial epithelium — a full-text finding from a single in vitro study — which would in principle work against mucolytic therapy in hypersecretory phenotypes. The rodent data point the other way (reduced goblet cell hyperplasia), so the net direction is genuinely unknown and no co-administration has been tested.
PMID 25015171 (in vitro, full text); PMID 26468022
Active lung cancer therapy (EGFR/ALK inhibitors, chemotherapy) or known lung adenocarcinoma
CautionTheoreticalThe cited paper actually describes NKX2-1 and FOXA1 as having opposite, histology-dependent roles in lung cancer, so 'these factors drive adenocarcinoma growth' is not a supportable claim. The caution instead rests on the peptide being an unstudied modulator of epithelial proliferation markers (Ki67) and the anti-apoptotic factor Mcl-1, with zero tumor-model or carcinogenicity data in either direction. Avoiding an untested proliferative-signalling agent during active oncologic treatment is prudence, not a demonstrated interaction.
PMID 22383183 (context-dependent roles); PMID 25015171
Immunosuppressants and biologics for autoimmune or interstitial lung disease (corticosteroids at immunosuppressive dose, rituximab, mycophenolate)
CautionTheoreticalReported enhancement of mucosal sIgA in rats and modulation of the airway immune compartment could theoretically counteract deliberate immunosuppression. Single rodent finding; no co-administration study in any species.
PMID 26468022
Inhaled corticosteroids (budesonide, fluticasone)
NeutralTheoreticalNo pharmacokinetic or pharmacodynamic overlap has been demonstrated — both act on airway epithelium but by unrelated pathways, and no interaction study exists in any species.
No published interaction study
Bronchodilators (beta-2 agonists, LAMA/SAMA anticholinergics)
NeutralTheoreticalNo reported activity at adrenergic or muscarinic receptors and no smooth-muscle effect has been measured, so no mechanistic basis for interference or synergy is established.
No published interaction study
Antifibrotics (pirfenidone, nintedanib)
NeutralTheoreticalThe only basis for expecting additive benefit is a bleomycin rat fibrosis report that is not indexed in PubMed, so it cannot support a directional claim. With no reliable anti-fibrotic data and no combination study in any species, neither synergy nor interference is established — and antifibrotics have narrow tolerability margins, so adding an uncharacterized agent is untested territory.
No primary fibrosis data; no combination study
CYP450-metabolized drugs generally (theophylline, macrolides, azoles)
NeutralTheoreticalAs a tetrapeptide expected to be cleared by ubiquitous peptidases rather than hepatic oxidation, there is no plausible CYP inhibition or induction liability — but this is inference only, as no CYP assay has been published.
Mechanistic inference; no CYP assay published
Known risks(9)
No human clinical trials — safety and efficacy in humans unestablished
Almost all research from single Russian research group (Khavinson) — no independent Western replication
Theoretical concern: gene expression modulation (NKX2-1, FOXA1/2) could affect pre-existing lung malignancies
Potential immune enhancement via sIgA upregulation may be contraindicated in autoimmune lung conditions
Long-term effects of chronic DNA-binding peptide administration unknown
Oral bioavailability not rigorously characterized in peer-reviewed studies
Quality varies significantly among unregulated products sold online — no pharmaceutical-grade manufacturing standards
Pregnancy and lactation safety data absent
Interactions with bronchodilators, corticosteroids, and immunosuppressants unstudied
Drug interactions(6)
Corticosteroids (inhaled/systemic)
Bronchogen modulates inflammatory cytokines and sIgA; concurrent corticosteroid use may produce competing immunomodulatory effects. No interaction studies conducted.
Bronchodilators (beta-2 agonists, anticholinergics)
Both target bronchial tissue through different mechanisms. No interaction data available. Theoretical synergy but unstudied.
Immunosuppressants
Bronchogen enhances local immune defense (sIgA); immunosuppressants work in opposition. Concurrent use may reduce efficacy of either agent.
Chonluten (EDG tripeptide)
Related Khavinson respiratory peptide. Both target bronchopulmonary tissue through complementary mechanisms. Used together in some Russian bioregulator protocols.
Other Khavinson peptides (Epithalon, Thymalin, Vilon)
Khavinson protocols often combine organ-specific bioregulators. No formal interaction studies but decades of reported combined use in Russian clinical practice.
Mucolytics (NAC, guaifenesin)
Both affect mucus production and airway secretions. No interaction data available.
Research & benefits
Evidence base
- Evidence Level
- Preclinical
- Total Studies
- 8
- Human Studies
- 0
All evidence derives from in vitro cell culture studies (human bronchial epithelial cell lines) and in vivo rat models (NO2-induced COPD). Research spans approximately 2006-2022 and originates almost entirely from Russian institutions affiliated with V.Kh. Khavinson. No independent replication by non-Russian research groups. No randomized controlled human trials. Evidence is promising but limited and lacks independent verification.
Researched for(8)
Rated by confidence in the evidence
Bronchial epithelial restoration
LowReversed epithelial damage in a rat COPD model and in vitro, no human trials yet.
PMID 26468022; PMID 25015171
Anti-inflammatory (respiratory)
LowReduced inflammatory markers and cell infiltration in a single rat COPD study.
PMID 26468022
Local immune defense enhancement
SpeculativeIncreased secretory IgA in one rat study, without any infection-clearance testing.
PMID 26468022
Surfactant production support
SpeculativeCell studies measured a surfactant-related gene; a separate rat COPD study measured increased surfactant protein B in bronchoalveolar lavage fluid (PMID 30199201).
PMID 25015171
DNA stabilization
SpeculativeA laboratory experiment directly measured DNA stabilization, reporting a 3.1°C increase in melting temperature; clinical significance remains unknown (PMID 21240358).
PMID 25015171
Gene regulation for lung health
LowModulated several lung-differentiation genes in cultured human cells, clinical relevance remains unproven.
PMID 25015171
Age-related tissue repair
SpeculativeBased on stronger effects in older cell cultures, not tested in aged animals or humans.
PMID 25015171
Anti-fibrotic potential
LowLessened, not prevented, lung fibrosis in a rat bleomycin model per the inventor's own patent filing.
US Patent 7,625,870 (Khavinson et al., filed 2004), Example 3 rat bleomycin fibrosis study; a patent disclosure, not a peer-reviewed or PubMed-indexed publication.
Benefits(8)
Bronchial epithelial restoration
Anti-inflammatory (respiratory)
Local immune defense enhancement
Surfactant production support
DNA stabilization
Gene regulation for lung health
Age-related tissue repair
Anti-fibrotic potential
Key studies(6)
Khavinson VKh, Tendler SM, Vanyushin BF, Kasyanenko NA, Kvetnoy IM, Linkova NS, Ashapkin VV, Polyakova VO, Basharina VS, Bernadotte A
Lung
2014
ADEL modulated Ki67, Mcl-1, p53, CD79, NOS-3 proteins and regulated NKX2-1, SCGB1A1, SCGB3A2, FOXA1, FOXA2 gene expression in bronchial epithelial cells. Binds DNA major groove at guanine residues.
Kuzubova NA, Lebedeva ES, Dvorakovskaya IV, Surkova EA, Platonova IS, Titova ON
Bull Exp Biol Med
2015
1-month Bronchogen treatment in NO2-induced COPD rats eliminated goblet cell hyperplasia, squamous metaplasia, lymphocytic infiltration, emphysema. Restored ciliated cells and enhanced sIgA production.
Monaselidze JR, Khavinson VKh, Gorgoshidze MZ, Khachidze DG, Lomidze EM, Jokhadze TA, Lezhava TA
Bull Exp Biol Med
2011
Bronchogen increased DNA melting temperature by 3.1 degrees C via strong, non-specific binding to nitrogenous bases. DNA-stabilizing effect observed at molar ratios 0.01-0.055.
Titova ON, Kuzubova NA, Lebedeva ES, Preobrazhenskaya TN, Surkova EA, Dvorakovskaya IV
Ross Fiziol Zh Im I M Sechenova
2017
Bronchogen reduced neutrophilic inflammation, normalized cytokine profiles, restored bronchial epithelial structure, and increased sIgA and surfactant protein B in COPD rat model.
Khavinson VKh, Linkova NS, Polyakova VO, Kheifets OV, Tarnovskaya SI, Kvetnoy IM
Bull Exp Biol Med
2012
Bronchogen (AEDL) stimulated CXCL12 and Hoxa3 differentiation markers in bronchial epithelial cultures, with stronger effects in aged cultures. WEGC1 findings concerned prostatic fibroblasts treated with vesugen.
Zakutskii AN, Chalisova NI, Ryzhak GA, Aniskina AI, Filippov SV, Zeziulin PN
Adv Gerontol
2006
Bronchogen at 0.05 ng/ml showed organ-specific stimulating effects in lung tissue cultures from both young and old rats, supporting reparative processes during aging.
Regulation & availability
Why researchers look at it
In animal models of COPD, Bronchogen reversed excess mucus-producing cells, tissue damage, and inflammation while restoring healthy ciliated cells and boosting local immune defenses — with preferential activity in aged tissue. All published research comes from a single group (the Khavinson lab in St. Petersburg), with no independent replication or controlled human trials in Western institutions. If independent researchers validate these findings, it could become a notable entry in respiratory peptide therapeutics.
- Estimated cost
- $30-80/mo oral capsules
- FDA status
- Bronchogen is not FDA-approved and is not eligible for compounding in the US. IND and NDA submission status is unconfirmed. FDA generally does not disclose whether an IND exists unless it has previously been publicly disclosed or acknowledged. In Russia, it is available as a dietary supplement (not a registered pharmaceutical).
- WADA status
- Not individually named in the 2026 list. S0 prohibits pharmacological substances without governmental approval for human therapeutic use. Confirm whether any qualifying approval exists before athletic use.
- Prescribability
- Research only (March 2026). Not FDA-approved. Available as dietary supplement in Russia and some Eastern European countries.
- Availability
- Available as an oral capsule supplement in Russia and Eastern European countries through the Peptide Bioregulator product line. Not available through standard US pharmacies or compounding pharmacies. Unregulated products are also sold online and vary in purity.
International status
EU
Not approved
US
Not approved
Russia
Used clinically (Khavinson bioregulator protocol)
Worldwide
Limited to Russian clinical use
Regulatory timeline(8)
- 1973-2000sKhavinson peptide program developmentV.Kh. Khavinson developed peptide bioregulators from animal tissue extracts at St. Petersburg Institute of Bioregulation and Gerontology. Bronchogen synthesized as short-peptide analog of bronchial mucosa extract.
- 2006First published organotypic tissue studyZakutskii et al. demonstrated tissue-specific effects of Bronchogen in lung cultures from young and old rats (Adv Gerontol).
- 2011DNA thermostability study publishedMonaselidze et al. showed Bronchogen stabilizes DNA, increasing melting temperature by 3.1 degrees C (Bull Exp Biol Med).
- 2012Age-related differentiation studyKhavinson et al. demonstrated tissue-specific stimulation of differentiation factors in aged bronchial epithelial cells (Bull Exp Biol Med).
- 2014Comprehensive gene regulation studyKhavinson et al. published key study in Lung journal showing ADEL regulation of NKX2-1, SCGB1A1, SCGB3A2, FOXA1, FOXA2 genes and DNA binding mechanism.
- 2015COPD rat model studyKuzubova et al. showed Bronchogen reverses COPD pathology in NO2-exposed rats (Bull Exp Biol Med).
- 2017Anti-inflammatory COPD studyTitova et al. confirmed anti-inflammatory and regenerative effects in COPD model with cytokine normalization and surfactant protein B restoration.
- 2026-03Current statusRemains research-only compound. No FDA approval pathway active. No human clinical trials registered on ClinicalTrials.gov.
Sources & FAQs
Research sources(7)
- Peptide regulation of gene expression and protein synthesis in bronchial epithelium
- Modulating Effect of Peptide Therapy on the Morphofunctional State of Bronchial Epithelium in Rats with Obstructive Lung Pathology
- Effect of the peptide bronchogen (Ala-Asp-Glu-Leu) on DNA thermostability
- Antiinflammatory and Regenerative Effect of Peptide Therapy in the Model of Obstructive Lung Pathology
- Peptides tissue-specifically stimulate cell differentiation during their aging
- The tissue-specific effect of synthetic peptides-biologic regulators in organotypic tissues culture in young and old rats
- Peptides Regulating Proliferative Activity and Inflammatory Pathways in THP-1 Cell Line (related Khavinson peptides)
Frequently asked questions(6)
What is Bronchogen?
Bronchogen is a synthetic tetrapeptide (Ala-Glu-Asp-Leu, or AEDL) bioregulator developed through the Khavinson peptide research program in Russia. It is designed to target bronchial and pulmonary tissue, modulating gene expression related to respiratory health.
Is Bronchogen safe?
Animal studies show a favorable safety profile with no significant adverse effects at research doses. However, no human clinical trials have been conducted, so safety in humans has not been formally established. The absence of observed toxicity in limited animal studies does not guarantee human safety.
How is Bronchogen administered?
Available as oral capsules, with courses repeated in Russian supplement practice. Oral formulations may use enteric coating for bioavailability.
Does Bronchogen have human clinical trial data?
No. All published evidence comes from in vitro cell culture studies and in vivo rat models. No randomized controlled human trials have been published in peer-reviewed journals.
How does Bronchogen differ from Chonluten?
Both are Khavinson respiratory peptides. Bronchogen (AEDL, tetrapeptide) targets bronchial epithelial cell differentiation and gene regulation. Chonluten (EDG, tripeptide) is derived from bronchial/lung tissue and has demonstrated TNF inhibition in monocyte studies.
Is there independent verification of Bronchogen research?
Almost all research originates from Russian institutions affiliated with V.Kh. Khavinson. One notable exception is a 2022 study in Int J Mol Sci by Avolio et al. (Italian/Russian collaboration) that studied related Khavinson peptides. Independent Western replication of Bronchogen-specific findings remains absent.